Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial

Phase 3

Active, not recruiting

Conditions: Solid Tumor

Interventions: Drug: Pertuzumab
Drug: Trastuzumab
Drug: Other Combination Anti-Cancer Therapies

First Posted Date: 2014-12-19

Last Posted Date: 2024-12-27

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 154

Registration Number: NCT02320435

Locations: 🇧🇷
Núcleo de Pesquisa São Camilo, Sao Paulo, São Paulo, Brazil
🇧🇷
Instituto Nacional de Cancer - INCa, Rio de Janeiro, Brazil
🇨🇳
West China Hospital, Sichuan University, Chengdu, China

and more 58 locations

A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and/or Locally Advanced Malignant Solid Tumors

Phase 1

Terminated

Conditions: Cancer

Interventions: Drug: RO6927005
Drug: gemcitabine
Drug: nab-paclitaxel

First Posted Date: 2014-12-16

Last Posted Date: 2016-07-26

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 15

Registration Number: NCT02317419

Prospective Observational Study on the Management of Patients With Relapsed or Refractory Follicular Lymphoma (OLYMPE)

Completed

Conditions: Follicular Lymphoma

Interventions: Drug: Rituximab

First Posted Date: 2014-12-15

Last Posted Date: 2016-02-25

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 260

Registration Number: NCT02316613

A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndromes

Interventions: Drug: RO6870810

First Posted Date: 2014-12-04

Last Posted Date: 2017-12-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 26

Registration Number: NCT02308761

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

An Observational Study of Continued Bevacizumab Plus Chemotherapy Until First Progression in Participants With Metastatic Colorectal Cancer (CRC)

Completed

Conditions: Colorectal Cancer

Interventions: Other: Bevacizumab
Combination Product: Chemotherapy

First Posted Date: 2014-12-02

Last Posted Date: 2018-08-23

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 300

Registration Number: NCT02305615

Locations: 🇭🇺
Debreceni Egyetem Klinikai Kozpont ; Department of Oncology, Debrecen, Hungary
🇭🇺
Szent Margit Hospital, Budapest, Hungary
🇭🇺
Semmelweis Egyetem Onkologiai Központ, Budapest, Hungary

and more 19 locations

An Observational Study of Kadcyla Safety in Breast Cancer

Completed

Conditions: Breast Cancer

First Posted Date: 2014-12-02

Last Posted Date: 2023-01-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 563

Registration Number: NCT02305641

Locations: 🇰🇷
Yeungnam University Medical Center; Surgical Department of Breast and Internal Secretion, Daegu, Korea, Republic of
🇰🇷
Kosin University Gospel Hospital, Busan, Korea, Republic of
🇰🇷
Dong-A University Hospital, Busan, Korea, Republic of

and more 35 locations

An Observational Study of Herceptin SC Safety in Breast Cancer

Completed

Conditions: Breast Cancer

First Posted Date: 2014-12-02

Last Posted Date: 2020-11-16

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 600

Registration Number: NCT02305628

Locations: 🇰🇷
Ulsan University Hosiptal, Ulsan, Korea, Republic of
🇰🇷
Hallym University Sacred Heart Hospital, Gyeonggi-do, Korea, Republic of
🇰🇷
Gachon University Gil Medical Center, Incheon, Korea, Republic of

and more 20 locations

A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: Atezolizumab
Drug: Selicrelumab

First Posted Date: 2014-12-01

Last Posted Date: 2019-12-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 140

Registration Number: NCT02304393

Locations: 🇩🇰
Rigshospitalet; Onkologisk Klinik, København Ø, Denmark
🇨🇦
University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, Canada
🇨🇦
Jewish General Hospital / McGill University, Montreal, Quebec, Canada

and more 8 locations

A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]

Phase 3

Completed

Conditions: Bladder Cancer

Interventions: Drug: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody
Drug: Docetaxel
Drug: Paclitaxel
Drug: Vinflunine

First Posted Date: 2014-11-27

Last Posted Date: 2019-08-01

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 931

Registration Number: NCT02302807

Locations: 🇷🇸
Oncology Institute of Vojvodina, Sremska Kamenica, Serbia
🇬🇧
Barts and The London, London, United Kingdom
🇨🇦
Tom Baker Cancer Centre-Calgary, Calgary, Alberta, Canada

and more 214 locations

A Study of RG7625 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Placebo
Drug: RG7625

First Posted Date: 2014-11-20

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 17

Registration Number: NCT02295332

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy